P584: OVERALL SURVIVAL WITH INTENSIVE CHEMOTHERAPY (IC) VS NON-IC IN PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AML FROM THE CONNECT® MYELOID DISEASE REGISTRY INELIGIBLE FOR RANDOMIZ... by H. Erba, D. Pollyea, M. Sekeres, G. Garcia-Manero, K. Seiter, I. DeGutis, P. Kiselev, A. McBride, E. Yu, G. Roboz

Get full text

P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTOR... by N. Jain, G. Roboz, M. Konopleva, H. Liu, G. Schiller, E. Jabbour, P. Desai, D. Whitfield, A. Haider, O. Zernovak, M. Frattini, C. Brownstein, R. Larson

Get full text

P555: A PHASE 1B/2 STUDY OF THE CD123-TARGETING ANTIBODY-DRUG CONJUGATE PIVEKIMAB SUNIRINE (IMGN632) IN COMBINATION WITH VENETOCLAX (VEN) AND AZACITIDINE (AZA) FOR PATIENTS WITH CD... by N. G. Daver, P. Montesinos, A. Aribi, G. Martinelli, J. Altman, G. Roboz, E. S. Wang, P. W. Burke, D. Jeyakumar, R. B. Walter, D. J. DeAngelo, H. P. Erba, A. Advani, L. Gastaud, X. Thomas, E. Todisco, N. Pemmaraju, L. Mendez, A. de la Fuente, G. Gaidano, A. Curti, N. Boissel, C. Recher, C. Schliemann, P. Vyas, C. M. Sloss, J. Wang, K. A. Malcolm, P. A. Zweidler-McKay, K. L. Sweet

Get full text